Internet live webcast on November 14, 2006 available at www.medigene.de Martinsried/Munich November 9, 2006. On the occation of the acquisition of Avidex Ltd., the biotech company MediGene AG (Frankfurt, Prime Standard: MDG) will host an analyst conference in Frankfurt on November 14, 2006, at 2 p.m. CET which will be webcast live. Dr. Peter Heinrich, MediGene's CEO, Alexander Dexne, CFO, Dr. Ulrich Delvos, Executive Board Member R&D, as well as Dr. Bent Jacobsen, Senior Vice President Research, Avidex Ltd., will present MediGene's new drug development projects and give an update on the company's current development programs and corporate strategy. The webcast is available on MediGene's website at http://www.medigene.de. Please log on at least 15 minutes before the conference starts to allow time for any software download that may be required to hear the webcast. A replay of the webcast will be available on the MediGene website. The conference will be held in English. MediGene possesses a mature drug pipeline with a drug available on the European market (Eligard® for the treatment of prostate cancer), another drug (Polyphenon® E Ointment for the treatment of genital warts) has been approved by the FDA. Several other drug candidates are in clinical development. In addition, MediGene owns cutting-edge platform technologies with the EndoTAG(TM), oncolytic HSV and mTCR (soluble T-cell receptor) technologies. The company's core competence lies in research and development of novel approaches in anti cancer and autoimmune therapies. The drug candidate EndoTAG(TM)-1 (clinical phase II in pancreatic cancer) aims at "starving out" tumors by destroying the supplying blood vessels. It builds on the successful new therapeutic principle of anti-angiogenesis (inhibition of vascularization), and yet provides an innovative variation thanks to its novel mode of action (vascular disruptive agent). RhuDex® is the first oral CD80 interactor and is developed for the treatment of rheumatoid arthritis. MediGene's innovative oncolytic HSV (herpes simplex viruses) (phase I/II in glioma and liver metastases) are modified for the selective destruction of tumor cells without harming healthy tissue. This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM and EndoTAGTM are trademarks of MediGene AG, Polyphenon® E is a trademark of Mitsui Norin, Eligard® is a trademark of Atrix Laboratories/Sanofi-Aventis. - Ends - MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A second drug, Polyphenon® E Ointment, has been approved by the FDA. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies. The company's core competence lies in research and development of novel approaches in anti cancer therapies. Thus MediGene focuses on indications of high medical need and great economic opportunities. Contact MediGene AG: Julia Hofmann / Dr. Georg Dönges, Public Relations: Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations: Tel.: ++49 - 89 - 85 65 - 2946 Email: [email protected] Fax: ++49 - 89 - 85 65 - 2920 --- End of Message --- WKN: 502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All Share, HDAX, MIDCAP, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;